Promaxo Announces Clinical Collaboration with Mount Sinai Health System and UTHealth Houston

Promaxo, a medical imaging, robotics, and AI technology company, announced clinical collaborations with Mount Sinai Health System, NY and UTHealth Houston, the University of Texas Health Science Center at Houston, TX. The clinical partnerships, focused on expanding the clinical utility of the Promaxo MRI to kidney cancers, pelvic floor abnormalities and prostate ablative treatments with gold nanoparticles, are being announced in conjunction with the ongoing American Society of Clinical Oncology Genitourinary Cancers (ASCO – GU) Symposium in San Francisco, CA, where Promaxo is hosting meetings with the GU-community.

NLP AiThority News : NLP Leader Huma.AI Launches Industry’s First Generative AI Platform for Life Sciences

Dr. Ketan Badani, Professor of Urology at the Icahn School of Medicine at Mount Sinai and Vice Chairman of Urology and Robotic Operations at the Mount Sinai Health System, said, “At Mount Sinai, we seek to improve the detection and treatment of cancers of the prostate and kidney with less invasive and effective technology. We are pleased to incorporate the Promaxo MRI to enable our clinicians with novel low-field MRI capabilities for diagnosing and improving prostate cancer treatment for our patients, and further investigate and expand the low-field MRI capabilities to patients with kidney lesions and pelvic floor abnormalities.”   The Mount Sinai Health System is a network of eight hospital campuses in New York City.

Further, Dr. Steven Canfield, Professor and Chair of the Division of Urology at McGovern Medical School at UTHealth Houston, added, “At UTHealth, we strive to provide the highest level of care to our patients and offer them the best clinical solutions available. We are looking forward to incorporating the novel low-field capabilities of Promaxo MRI to enable our clinicians in delivering better prostate biopsies and treatments, including the AuroLase gold nanoparticles directed ablation for prostate cancer.” Located in the Texas Medical Center, UTHealth Houston is considered the largest medical center in the world.

Read More NLP News: Lion Announces It Will Explore ChatGPT Related AI & NLP Technologies To Empower Digital Program

“We are excited to announce new clinical programs that leverage the Promaxo MRI to advance current cancer treatments not only in the prostate, but also in the kidney and pelvis. We believe our partnerships with renowned institutions reinforce the flexibility of our portable and compact system to help establish new protocols in academia, as well as in larger clinical settings,” said Dr. Amit Vohra, Founder and CEO of Promaxo. “We remain focused on growing our business and driving market penetration of our single sided MR system, as we redefine the standard of care.”

Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo MRI system.

 Latest Hybrid Natural Language Insights : Expert.ai Announces New Features to Hybrid Natural Language Platform

 [To share your insights with us, please write to sghosh@martechseries.com]